B1NT34.SA BIONTECH SE DRN
- Market cap
- BRL 122B
- P/E
- -
- P/B
- 1.11x
- ROE
- -8.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is B1NT34.SA undervalued?
Graham numberThe Graham number of BIONTECH SE DRN cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BIONTECH SE DRN fundamental analysis
No fundamental analysis for BIONTECH SE DRN yet.
BIONTECH SE DRN stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BIONTECH SE DRN
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast ca…
Full company profileBIONTECH SE DRN financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BIONTECH SE DRN annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 61.6M | 128M | 109M | 482M | 19.0B | 17.3B | 3.82B | 2.75B | 2.87B | 2.02B |
| Gross Profit | 52.3M | 114M | 91.2M | 423M | 16.1B | 14.3B | 3.22B | 2.34B | 2.42B | 1.65B |
| Operating Income | -61.3M | -53.9M | -182M | -82.4M | 15.3B | 12.6B | 690M | -1.31B | -1.41B | -1.97B |
| EBITDA | - | -24.0M | -144M | -105M | 15.1B | 13.1B | 1.38B | -363M | -654M | -623M |
| Net Income | -85.7M | -48.0M | -179M | 15.2M | 10.3B | 9.43B | 930M | -665M | -1.14B | -1.56B |
| EPS | - | -0.21 | -0.79 | 0.06 | 42 | 39 | 3.91 | -2.77 | -4.52 | -6.28 |
| Balance Sheet | ||||||||||
| Total Assets | 375M | 653M | 798M | 2.32B | 15.8B | 23.3B | 23.0B | 22.5B | 22.0B | 20.2B |
| Total Liabilities | 424M | 387M | 304M | 947M | 3.94B | 3.22B | 2.76B | 3.12B | 2.76B | 2.46B |
| Shareholders' Equity | -49.3M | 266M | 493M | 1.37B | 11.9B | 20.1B | 20.2B | 19.4B | 19.2B | 17.7B |
| Cash & Short-term Investments | 172M | 412M | 521M | 1.35B | 2.07B | 14.1B | 16.5B | 16.8B | 14.9B | 10.2B |
| Cash Flow | ||||||||||
| Operating Cash Flow | -52.6M | -58.9M | -199M | -13.5M | 890M | 13.6B | 5.37B | 208M | 456M | -720M |
| Capital Expenditure | 57.7M | 29.9M | 38.6M | 66.0M | 128M | 363M | 706M | 452M | 749M | 244M |
| Free Cash Flow | - | -126M | -270M | -98.9M | 736M | 13.2B | 4.67B | -245M | -293M | -964M |
| Ratios | ||||||||||
| ROE | - | -18.0% | -36.3% | 1.1% | 86.5% | 47.0% | 4.6% | -3.4% | -5.9% | -8.8% |
| ROA | -22.9% | -7.4% | -22.4% | 0.7% | 65.0% | 40.5% | 4.0% | -3.0% | -5.2% | -7.7% |
| Net Profit Margin | -139.1% | -37.6% | -164.9% | 3.2% | 54.2% | 54.5% | 24.4% | -24.2% | -39.6% | -77.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
BIONTECH SE DRN dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 2, 2022
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | EUR 484M | 1.99 | 5.1% |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Nov 21, 2022.
Who owns BIONTECH SE DRN
Ownership data of BIONTECH SE DRN is not available yet.
BIONTECH SE DRN company profile
- Company name
- BIONTECH SE DRN
- Ticker
- B1NT34.SA
- Exchange
- Sao Paulo Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 7,807
- Fiscal year end
- December
- Address
- An der Goldgrube 12, Mainz, Germany, 55131
- Phone
- 49 6131 9084
- Website
- biontech.de
About BIONTECH SE DRN
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.
BIONTECH SE DRN management
10- Dr. Ugur Sahin M.D.Co-Founder, CEO & Chair of the Management Board · born 1965
- Dr. Ozlem Tureci M.D.Co-Founder, Chief Medical Officer & Member of Management Board · born 1967
- Mr. Ramon Zapata-GomezCFO & Member of Management Board · born 1974
- Dr. Sierk Pötting Ph.D.MD, COO & Member of Management Board · born 1973
- Dr. James Timothy Patrick Ryan Ph.D.Chief Legal & Business Officer and Member of the Management Board · born 1975
- Ms. Annemarie HanekampChief Commercial Officer & Member of Management Board · born 1980
- Ms. Kylie JimenezChief People Officer & Member of Management Board · born 1976
- Ms. Lisa BirringerSenior Vice President of Global Financial Reporting & Accounting
- Mr. Douglas Maffei Ph.D.Vice President of Strategy & Investor Relations
- Jasmina AlatovicVice President Corporate Communications